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Necrobiosis lipoidica is a rare disorder that usually appears in the lower extremities and it is often related to diabetes mellitus. There
are few reported cases of necrobiosis lipoidica in children. We present an interesting case in that the patient developed lesions on
the abdomen, which is an unusual location.
1. Case Report
A 16-years-old girl, with type 1 diabetes diagnosed else-
where in 2000, was brought to our Department for a
first routine visit in 2006, during which two yellow-brown,
atrophic plaques surrounded by raised, violaceus rims on
the right side of the lower abdomen (0.79 × 0.2 in and
1.38×0.79 cm, resp.) (Figure 1) were observed. Several other
plaques had been observed on both legs (Figure 2). No
other significant finding had been seen. A careful history
revealed that she was on bad terms with her diabetes.
Since diagnosis she had a multiple daily injections (MDIs)
scheme for her insulin therapy (mean insulin requirement:
0.97U/kg/day). Due to poor glycemic control she was
switched to insulin pump therapy in 2006. Despite a slight
improvement in glycemic values and reduction in insulin
requirement (0.70U/kg/day), her glycated hemoglobin
(HbA1c) remained high (mean± SD: 12.9± 1.1), without
any improvement of the skin lesions. In 2008 she returned to
MDI, and her last HbA1c (December 2010) was 12.8%, with
an increasing insulin requirement (1.58U/kg/day). Topical
steroids were unhelpful in improving skin lesions.
2. Discussion
Necrobiosis lipoidica (NL) is an idiopathic dermatological
condition that is strongly associated with diabetes mellitus,
so much so that some authors name it “diabeticorum.”
NL is characterized by a rash that occurs on the lower
legs and only rarely on hands, fingers, face, and scalp [1].
It is noteworthy that, in our patient, beyond the usual
presentation on the legs, two skin lesions appeared on the
lower part of the abdomen.
At the beginning, the lesions appeared as erythematous
circle papules that then evolve to well-demarcated, atrophic,
shiny, yellow-brown telangiectasic multiple and bilateral
plaques. Except as they are ulcerated, the lesions are generally
asymptomatic [2]. NL is more common in women than
in men [1], and it appears usually in young or middle
adulthood [3]; few cases have been, however, reported in
childhood [4]. NL prevalence varies from 0.3% to 1.2%
among diabetic patients [2], two-thirds of whom have type
1 diabetes.
The pathogenesis of NL is largely enigmatic. It has been
suggested that NL is one of the possible manifestations of
microangiopathy, due to its clear association with diabetes.
Some authors [5] suggest that in patients with diabetes NL
might be a warning sign for nephropathy and retinopathy.
Whether or not poor glucose control is associated with the
development and progression of NL lesion remains contro-
versial [6]. Despite its possible role in NL pathogenesis, tight
glycemic control might prevent NL or even improve skin
lesions, when present [6].
Few data exist in pediatric population. A recent paper
by Pavlovic´ et al. [7] reported an NL incidence of 2.3%,
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Figure 1: Yellow-brown, atrophic plaques surrounded by raised, violaceus rims on the right side of the lower abdomen (a); particular of the
skin lesions (b).
(a) (b)
Figure 2: Skin lesions typically appear on the legs (a); particular of the skin lesions (b).
higher than that reported in the literature; there are 5
patients (4 females and 1 male) out of 212 patients with
type 1 diabetes (mean age 14 years, mean disease duration
7 years); no significant relationship has been observed with
disease duration, age, glycemic control. After a review of
our patients, we have found 3 patients with NL out of
240 (1.25%), 2 females and 1 male. All of them have
poor glycemic control (mean HbA1c: 13.4 ± 2.1%), initial
sign of microangiopathic complications (2 nephropathy,
3 neuropathy, 1 retinopathy). However, glycemic control
per se is not suggestive of NL appearance. Indeed, in our
population only 3 patients out of the about 30 with a steady
HbA1c value above 9% developed NL, confirming that other
factors have to be involved in NL pathogenesis. The finding
of IgM, IgG, IgA, and C3 in blood vessel walls might support
the role of immunological-mediated vascular disease in NL.
Some authors [8] regard NL to be a primary disease of
collagen, with inflammation occurring as a second event.
For this reason a strict avoidance of trauma is suggested to
prevent ulceration and the development of new lesions.
NL diagnosis is commonly a clinical one; only in those
few cases, usually in the starting stages of the disease, when
the diagnosis may be awkward, a biopsy of the lesion can be
useful.
Treatment of NL is often diﬃcult. First-line therapies
include smoking cessation and diabetes control improve-
ment. In addition, topical and intralesional corticosteroid
may be eﬀective [9], even if they can increase glycemic values.
In the present case, no improvement of the skin lesions
has been observed despite the use of topical corticosteroid.
A possible explanation could be the steady bad glycemic
control of the patient.
Recently, a new therapeutic attempt has been reported,
including topical PUVA photochemotherapy [10]: after a
mean of 47 sessions all 10 treated patients experienced almost
complete remission of the skin lesions.
On the other side, systemic therapies using corticos-
teroids and azathioprine could facilitate malignant transfor-
mation [11]. Squamous cell carcinomas have been reported
to arise in areas of NL [11].
Diﬀerential diagnosis includes granuloma annulare, sar-
coidosis, and amyloidosis. Granuloma annulare has typical
lesions with epidermis not thinned. Besides the histopatho-
logic findings that may rule out the diﬀerences between
the diseases, it shows resolution with near restoration of
structure, normal and without sclerosis. On the other hand,
necrobiosis lipoidica shows a progression to collagen bundles
in the reticular dermis in septa in the subcutaneous fat
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becoming crowded and thickened. Sarcoidosis is a multi-
system disease that may involve almost any organ system,
and its dermatological findings can assume a vast array of
morphologies. Correctly diagnosing sarcoidosis may be a
challenge. Patients are diagnosed with sarcoidosis when a
compatible clinical or radiologic picture is present, along
with histologic evidence of noncaseating granulomas, and
when other potential causes, such as infections, are excluded.
Amyloidosis is a systemic disease too, a plasma-cell dyscrasia
of unknown cause, with well-recognized dermatological
signs that may be the presenting features. Skin and soft-
tissue lesions may, indeed, be the only manifestations of
the disease prior to later-stage organ involvement. Although
the skin manifestations of systemic amyloid are common
to many conditions, their presentation in certain clinical
settings should help to indicate this disorder for inclusion in
the diﬀerential diagnosis.
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